Catalog No.
FHC31210
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
SLC3A2, 4F2hc, Lymphocyte activation antigen 4F2 large subunit, CD98, 4F2 cell-surface antigen heavy chain, Solute carrier family 3 member 2, MDU1, 4F2 heavy chain antigen
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08195
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Ab110
Targeting LAT1 with JPH203 to reduce TNBC proliferation and reshape suppressive immune microenvironment by blocking essential amino acid uptake., PMID:40379991
Suppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion., PMID:40073262
Comparative Radiotracing Quantifies Brain Cellular Uptake and Catabolism of Bispecific Antibodies Targeting Transferrin Receptor and CD98hc., PMID:40071777
A genome wide CRISPR screen reveals novel determinants of long-lived plasma cell secretory capacity., PMID:40060628
AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity., PMID:40046051
Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution., PMID:39979268
Expression rate of LAT1 in high-grade parotid gland carcinoma and potential of BNCT as a treatment option for recurrent parotid gland carcinoma., PMID:39837206
Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors., PMID:39755583
Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression., PMID:39639312
Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors., PMID:39600127
Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners., PMID:39433176
A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts., PMID:39261363
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy., PMID:39095551
Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development., PMID:39061168
Upregulation of Transferrin Receptor 1 (TfR1) but Not Glucose Transporter 1 (GLUT1) or CD98hc at the Blood-Brain Barrier in Response to Valproic Acid., PMID:39056763
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy., PMID:39041287
Multilayered proteomics reveals that JAM-A promotes breast cancer progression via regulation of amino acid transporter LAT1., PMID:38943512
Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia., PMID:38914715
CD147 regulates the formation and function of immune synapses., PMID:38909549
Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system., PMID:38726007
Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy., PMID:38460518
Functional and Immunologic Mapping of Domains of the Reticulocyte-Binding Protein Plasmodium vivax PvRBP2a., PMID:38441336
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade., PMID:38429349
HERV-K (HML-2) Envelope Protein Induces Mitochondrial Depolarization and Neurotoxicity via Endolysosome Iron Dyshomeostasis., PMID:38383499
The role of EDIL3 in maintaining cartilage extracellular matrix and inhibiting osteoarthritis development., PMID:38081212
Targeted transport of biotherapeutics at the blood-brain barrier., PMID:38059358
CD147: an integral and potential molecule to abrogate hallmarks of cancer., PMID:38023152
Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer., PMID:37731509
Comprehensive cell surface protein profiling of human mesenchymal stromal cells from peritoneal dialysis effluent and comparison with those from human bone marrow and adipose tissue., PMID:37603218
CD98hc is a target for brain delivery of biotherapeutics., PMID:37598178
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer., PMID:37559159
Early appearance of functional plasma cells (CD138+CD98+) in non-immunized neonate mice., PMID:37225058
Unraveling CD69 signaling pathways, ligands and laterally associated molecules., PMID:37223078
Advanced Boron Neutron Capture Therapy Targeting Cancer Stem Cells by Selective Induction of LAT1 Overexpression., PMID:37212749
CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2/CD98 antibody inhibits the growth signal of human breast cancer cells., PMID:36811310
An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice., PMID:36424464
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis., PMID:36257298
HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition., PMID:36151255
Endocytosis-Independent and Cancer-Selective Cytosolic Protein Delivery via Reversible Tagging with LAT1 substrate., PMID:35789055
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study., PMID:35628616
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy., PMID:35577502
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer., PMID:35317825
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain., PMID:35171652
Galectin-3 enhances atrial remodelling and arrhythmogenesis through CD98 signalling., PMID:34995420
Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer., PMID:34981670
Plasma Membrane Receptors Involved in the Binding and Response of Osteoclasts to Noncellular Components of the Bone., PMID:34576260
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target., PMID:34194623
Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2., PMID:34112739
Biological drug and drug delivery-mediated immunotherapy., PMID:33996408
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy., PMID:33974508
For research use only. Not for human or drug use.
